The Swords Campus of SK Biotek Ireland will receive a $35 million investment from SK Pharmteco as part of a new expansion plan.

A $35 million investment for the first stage of an expansion plan for SK Biotek Ireland’s pharmaceutical manufacturing facility in Dublin has been announced by SK Pharmteco (SKPT), a worldwide CDMO and division of SK Inc.

The site’s manufacturing capacity and capabilities will significantly grow as a result of this initiative, benefiting its international clientele. The new structure will open in 2024, the year the Swords Campus celebrates 60 years of producing small molecule active pharmaceutical ingredients. Patients will then have access to some of the top therapies in the world, including a number of oncology and cardiology medications.

The expansion will happen over two phases, phase 1 of the project will include a new manufacturing facility, increasing reactor volume capacity by 26.5 m3, along with utilities, filtration and drying equipment, and the option to add more manufacturing lines and technologies in following phases.

The new facility will be situated near to other site facilities on the site’s demolished industrial building’s footprint.

When the project is finished, the Swords Campus’s capacity will have increased by 50% overall.

We use cookies to give you the best online experience. By agreeing you consent the use of cookies in accordance with our Privacy Statement and cookie settings in your Privacy Settings below.

Privacy Settings saved!
Privacy Settings

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie

Decline all Services
Accept all Services